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ABSTRACT
MicroRNAs (miRNAs) are released from cells in association with proteins or microvesicles. We previously reported that malignant transformation
changes the assortment of released miRNAs by
affecting whether a particular miRNA species is
released or retained by the cell. How this selectivity
occurs is unclear. Here we report that selectively
exported miRNAs, whose release is increased in
malignant cells, are packaged in structures that
are different from those that carry neutrally
released miRNAs (n-miRNAs), whose release is not
affected by malignancy. By separating breast cancer
cell microvesicles, we find that selectively released
miRNAs associate with exosomes and nucleosomes. However, n-miRNAs of breast cancer cells
associate with unconventional exosomes, which are
larger than conventional exosomes and enriched in
CD44, a protein relevant to breast cancer metastasis. Based on their large size, we call these vesicles
L-exosomes. Contrary to the distribution of miRNAs
among different microvesicles of breast cancer
cells, normal cells release all measured miRNAs in
a single type of vesicle. Our results suggest that
malignant transformation alters the pathways
through which specific miRNAs are exported from
cells. These changes in the particles and their

miRNA cargo could be used to detect
presence of malignant cells in the body.

the

INTRODUCTION
MicroRNAs (miRNA) are short non-coding RNA
molecules that modulate the activity of speciﬁc mRNA
targets in normal development and disease, typically by
compromising messenger RNA (mRNA) stability.
MiRNAs are released by cells in a variety of vesicles or
associated in complexes with proteins [reviewed in (1)].
Exosomes were the ﬁrst extracellular vesicles shown to
contain miRNA (2–12). Exosomes originate from
multivesicular bodies (MVBs) of the endosomal compartment and may contain miRNA as a consequence of
loading into the RNA-induced silencing complex and unloading at the MVBs (13,14).
The association of miRNA with exosomes is signiﬁcant,
in that exosomes can transfer cancer-speciﬁc molecules to
other cells (15,16). Through this transfer of material,
exosomes have been shown to contribute to tumor progression (Duelli et al., 2005), modiﬁcation of the microenvironment (17) and the host (18), through induction of
angiogenesis, production of niches for metastasis (19,20)
and immune modulation (21–25). The packaging and
export of miRNAs from cells and delivery of them to
other cells may be important processes for extracellular
miRNA-signaling pathways, although these mechanisms
are not well understood.
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up-regulated in pre-neoplastic syndromes (56) and has
roles in p63 regulation and cell differentiation (57–59).
The importance and roles of these vesicular miRNAs in
cancer and in the extracellular environment are beginning
to emerge. However, much remains to be determined regarding the nature of the vesicles that shuttle these
miRNAs outside of the cell.
The observations that cells can selectively release
miRNAs and also release a heterogeneous population of
vesicles raise the possibility that the differential release of
miRNAs is associated with different microvesicles. We
thus analyzed the nature of the microvesicles that are
associated with s-miRNAs. We ﬁnd that s-miRNAs
and n-miRNAs are released from cells in different types
of particles. The identiﬁcation and puriﬁcation of
sub-populations of extracellular microvesicles that carry
distinct miRNA cargo allows for the possible assignment
of the subcellular origin, extracellular function and
cellular targets of these vesicles, as well as for the development of cancer diagnosis and prognosis based on the
association of speciﬁc miRNA with speciﬁc extracellular
vesicles.

MATERIALS AND METHODS
MDA-MB-231 and MCF7 cells were purchased from
ATCC (Manassas, VA, USA) and maintained according
to the provider’s recommendations. Normal skin ﬁbroblasts were a gift from Dr. Beverly Davidson, University
of Iowa, and were grown in Minimum Essential Medium
Eagle With Earle’s salts (MEME) supplemented with
Nonessential amino acids (NEAA), glutamine and
pyruvate.
Cell culture
Exosomes and other particulates were collected from cells
in culture as described (30). In brief, after 5 days of
culturing in deﬁned media, media were collected,
centrifuged at 300g for 15 min and passed through a
0.45-mm ﬁlter (Pall Acrodisc, Cornwall, UK) to remove
cell debris. The supernatant was centrifuged at 70 000g
to collect particulates including exosomes and
re-suspended with 100 ml phosphate buffered saline
(PBS). Cells for miRNA analysis were cultured in
deﬁned media for 5 days prior to collection. Routinely
breast cancer cell lines (1.2–1.6  109 cells) were maintained in Nunc Cell Factories (Nunc, Rochester, NY,
USA) or 15 cm plates for each experiment.
Deﬁned media
Deﬁned media were used to replace media containing fetal
bovine serum for vesicle and particle collection. Deﬁned
media were supplemented with Nutridoma-SP (Roche
Applied Science, Indianapolis, IN, USA), Na-pyruvate,
non-essential amino acids and L-Glutamine (all
Mediatech, Manassas, VA, USA) in DMEM/high
glucose (HyClone, Logan, UT, USA) in the absence of
serum. MCF-7 cells were cultured as described (30).
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Exosomes are perhaps the best studied of extracellular
vesicles, although some cells, in particular tumor cells,
actually release a heterogeneous population of microvesicles of uncertain subcellular origin (reviewed in
(1,26)). Recent work suggests that the proﬁle of
microvesicles released from cells may be indicative of the
cell type or cell state and may play an important role in
cell–cell transfer and communication. For example, solid
tumor cells, including breast cancer cells, release heterogeneous microvesicles that contain a variety of molecules
(27,28) that can be transferred to recipient cells and inﬂuence signaling pathways (29). Although miRNA has been
established as cargo of exosomes, the miRNA distribution
in cells that release multiple vesicles is not known.
We recently demonstrated that miRNAs are released
from breast cancer cells in a selective manner. We have
identiﬁed three categories of released miRNA in
mammary epithelial cells, which were classiﬁed based on
the ratio between the amount of miRNA released from the
cells and the amount retained in the cell (Table 1) (30).
The ﬁrst group is selectively released miRNAs, or
‘s-miRNA’. These miRNAs are characterized by being
released excessively from breast cancer cells with relatively
low concentrations of miRNA remaining in the cell.
Alternatively, normal cells release nearly none of these
miRNAs (30). Another group of miRNAs is in equal
abundance within the cell and extracellularly, i.e. neutrally
released miRNA, ‘n-miRNAs’ (30). N-miRNAs include
putative biomarkers miR-16, miR-21 and other miRNAs
for which the abundance in microvesicles reﬂects the
increased abundance in the malignant cells of origin.
The selectivity of release of individual miRNAs, and
thereby their categorical grouping, differs depending on
the cell type (6,9,12,30,31). In particular, selection is
affected by malignant transformation. For example, malignant mammary epithelia release >99% of miR-451 and
miR-1246 produced by the cells, while in benign epithelial
cells these miRNAs are mostly retained (30). Both of these
s-miRNAs are linked to cancer. MiR-451 is a tumor
suppressor (32), affecting proliferation (33,34) and cell
polarity (35), by deregulating several oncogenic
pathways (36–39). MiR-451 also induces sensitivity to
chemotherapeutic drugs (40,41), allows adaptation to
metabolic stress (42,43) and can induce endocrine resistance in breast cancer cells (44). MiR-1246 induces
p53-dependent apoptosis triggered by DNA damage
(45). The changes in the release of cancer-related
miRNAs may suggest a role for selective miRNA export
in malignant transformation, and it may provide a cancer
signature within the exported, circulating miRNA
population.
N-miRNAs include miR-16 and miR-720 (30). MiR-16
is one of the ﬁrst miRNAs identiﬁed to have tumorsuppressor activity (46,47), and circulating miR-16 is currently being evaluated as a serum marker for diagnosis or
prognosis of several cancers (48,49) and pre-malignant
syndromes (50). MiR-16 regulates chemosensitivity (51),
apoptosis (52) and the cell cycle (53), while its biogenesis is
induced by radiation (54) and is modulated by p53 (55).
MiR-720 is the most abundantly released miRNA from
malignant mammary epithelial cells (30). MiR-720 is
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Table 1. MiRNA that are differentially retained and exported in benign and malignant mammary epithelial cells (30)
Release

Selective

miR-16
miR-720
miR-451
miR-1246

Benign

Malignant

Cell

Microvesicle

Cell

Microvesicle

+++
++
+
+

++
++
–
–

+++
+++
+/+

++
+++
++
++

Neutrally released miRNAs (n-miRNAs): the most consistently released miRNA of human mammary epithelial cells irrespective of malignancy is miR-16. MiR-720 is the most abundantly released miRNA of breast cancer cells tested. It is consistently released from both benign
and malignant mammary epithelial cells. Selectively released miRNAs (s-miRNAs): cellular concentrations of miR-1246 and miR-451 are
similar in benign and malignant cells; however, the release of these miRNAs is selective and excessive from malignant cells. + relative
abundance in population by qRT–PCR and array; – not detectable in microvesicles; ± near threshold of detection.

P70/S70 preparation
Conditioned media or milk was cleared of cells and cell
debris by low-speed centrifugation (300g) and ﬁltration
(0.45 mm), followed by concentration of the remaining
particulates at 70 000g for 1 h. The pellet was washed in
PBS by re-suspension and centrifuged again at 70 000g.
We chose this centrifugation speed over conventional higher speed preparations (60) because vesicles
prepared at higher speeds do not retain complete biological activity (61).
Gradient preparation and centrifugation
Sucrose density gradients ranging from 2.0 to 0.25 M
sucrose in PBS were prepared. P70 samples were
re-suspended in 100 ml PBS, diluted to 1 ml in 2.5 M
sucrose and loaded into the bottom of the gradient. A
1 ml 2.5 M sucrose cushion was loaded below the
sample. Sucrose gradients were centrifuged at 100 000g
ranging from 0 h to equilibrium (48–90 h).

(BioRad, Hercules, CA, USA). For western blots, 500 ml
of each sucrose gradient fraction was diluted to 12 ml in
PBS and pelleted at 100 000g for 2 h. The pellet was
re-suspended in 100 ml Laemmli Buffer and 20 ml were
loaded per lane onto an 18% sodium dodecyl sulphate
(SDS)–polyacrylamide gel electrophoresis mini-gel and
then electrophoresed at 200 V for 45 min. The gel was
then transferred to Immobilon-FL (Millipore). Both
ﬂuorescently tagged secondary antibodies and horseradish
peroxidase (HRP)-tagged secondary antibodies were used.
For both dot blots and western blots, antibody binding
was quantiﬁed using a Typhoon 9400 (GE Healthcare,
Piscataway, NJ, USA) and goat-anti-mouse IgG-Alexa
488 or goat-anti-rabbit IgG-Alexa 488 (Invitrogen,
Grand Island, NY, USA) and ImageQuant T software.
Antigenicity was determined by quantifying antibodies
bound to dot-blotted P70. Subsequently, the blots were
developed for HRP activity using Luminata Classico
Western HRP substrate (EMD Millipore Corporation).

Negative-staining electron microscopy

Immunoprecipitation

All samples were adsorbed to Formvar-coated grids
followed by negative staining with 2% (w/v) sodium
phosphotungstate. Samples of sucrose gradient fractions
were passed through MicroSpin G-25 columns (GE
Healthcare, Piscataway, NJ, USA) to remove sucrose for
microscopy prior to ﬁxation. Micrographs were visualized
using a transmission electron microscope (JEM-2100, Jeol,
Tokyo, Japan).

Anti-CD59 antibodies (Millipore) were bound to
Dynabeads (Invitrogen) in PBS. P70 was applied to
CD59-bound Dynabeads. Supernatant containing CD59depleated P70 was captured on magnets, washed with
PBS and re-suspended in Laemmli Buffer. Captured particles were lysed from Dynabeads in Laemmli Buffer.

Dot blots and western blots

A 300 ml aliquot of each sucrose fraction, or Dynabeads in
PBS, was added to 500 ml Trizol reagent according to the
manufacturer’s instructions (Invitrogen). A synthetic
RNA (SYNTH, 250 fmol/ml (62)) was added as indicated
as a recovery control.

Dot blots and western blots were prepared using antibodies as described (30). Antibodies against CD147,
CD55, CD59, CD63, CD81, H2Ax and g-H2Ax
(Millipore, Billerica, MA, USA), CD44H (CD44s, R&D
Systems, Temecula, CA, USA), Glut-1 (Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA), CD98
(Pharmingen, BD Biosciences, San Diego, CA, USA)
and human leucocyte antigens (HLA) (AbD Serotec,
Raleigh, NC, USA) were used. In brief, P70s and other
preparations were re-suspended in PBS and blotted onto
Immobilon FL (Millipore) or nitrocellulose (Whatman,
Kent, UK) using a Bio-Dot Filtration Apparatus

RNA extraction

MiRNA detection
End-point PCR
Ten microliters of the 20 ml total RNA preparation was
used as input into a Superscript III (Invitrogen) reverse
transcriptase (RT) reaction with miRNA-speciﬁc stem–
loop primers as described (30).
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Standardization and normalization

50 End labeling of RNA
RNA (50 pmol) isolated from MDA-MB-231 P70
gradient fractions was enriched for small RNAs using
PureLink followed by treatment with with Antarctic phosphatase (NEB, Ipswich, MA) according to manufacturers
protocol. Dephosphorylated RNA was 50 end labeled
using T4 polynucleotide kinase (-30 phosphatase minus;
NEB) and 32P-g-adenosine triphosphate (ATP) according
to the manufacturers instructions. Radiolabeled RNA was
separated on a 12% urea-polyacrylamide gel.
Size quantitation of particles
Particle sizes were determined from electron microscopy
(EM) micrographs using NIS-Elements (Nikon, Melville,
NY). At least 100 particles were counted for each sample.
Milk
Milk was donated from the Mother’s Milk Bank of Iowa
(The University of Iowa Children’s Hospital) and the
Indiana Mother’s Milk Bank, Inc. Eight hundred microliters of milk from three mothers each was analyzed to
determine miRNA composition. The study was
approved by the institutional review board of the
Rosalind Franklin University of Medicine and Science.
In situ hybridization and immunoﬂuorescence
In brief, MDA-MB-231 cells were grown on coverslips,
ﬁxed in paraformaldehyde and washed in imidazole
buffer; miRNAs were immobilized with EDC 1-ethyl-3(3-dimethylaminopropyl) carbodiimide buffer (64) and
hybridized with 4 pmol of biotinylated miRCURY LNA
probes (Exiqon, Woburn, MA) for 16 h at 42 C and
probed with avidin to detect LNA probes (65).
Subsequently, cells were probed for CD63 using

Transduction
MDA-MB-231 cells were transduced with Green
Fluorescent Protein (GFP), caspase-8DN, caspase-9DN
or BCL2 in pBABEpuro by retroviral transduction,
selected for puromycin resistance and expression of
proteins conﬁrmed as described (66).
Induction of cell death
MDA-MB-231 cells were treated with 100 mM etoposide
for 24–72 h as described (66), or left untreated, and cell
death was quantiﬁed using trypan blue.
RESULTS
Breast cancer cells release a variety of particles
The differential release of s-miRNAs and n-miRNAs from
cells could be a consequence of the mode of export. Thus,
we ﬁrst tested whether s-miRNAs are associated with
the same extracellular particles as n-miRNAs. To do
so, we performed a crude microvesicle preparation of
MDA-MB-231 cells by ﬁltration and ultracentrifugation,
which yields a sample called P70 (30). We analyzed the
P70 by EM and found that this preparation contained
a variety of particles. Some particles had a cup shape
and size (50–100 nm) typical of exosomes (Figure 1A).
Other particles were either cup shaped or spherical and
a wide range of sizes, measuring 20–410 nm in diameter
(Figure 1B). These results indicate that malignant
mammary epithelial cells release a variety of vesicles and
particles into the extracellular environment. The presence
of a multitude of distinct particles in the extracellular
environment of breast cancer cells raises the question
whether speciﬁc miRNA subspecies associate with
speciﬁc microvesicles.
MiRNAs associate with sub-populations of microvesicles
This heterogeneity of released particles from breast cancer
cells (Figure 1A and B) is in contrast to the homogenous
population of exosomes released by normal ﬁbroblasts
(61). Furthermore, normal ﬁbroblasts export s-miRNAs
neutrally rather than selectively (30). Therefore, we
hypothesized that the diversity of vesicles could be
related to the differences in the assortment of the
released miRNAs in breast cancer cells. To test this idea,
we determined the distribution of small RNAs among the
vesicles. To do so, the P70 microvesicle preparation was
separated by buoyant sucrose gradient centrifugation,
which separates particles based on buoyant density
(Figure 1C). RNA was isolated from all gradient fractions
and the abundance of n-miRNAs and s-miRNAs in each
fraction was measured by quantitative reverse transcriptase–polymerase chain reaction (qRT–PCR) or gel electrophoresis. We found that distinct miRNAs associated with
different fractions of the gradient. For example, the
s-miRNA miR-1246 was present in different fractions
than the other miRNAs. Furthermore, none of the
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To ensure standardized input, exactly 300 ml of each 1 ml
fraction collected from the gradients (1–12) was extracted
using TRIzol as described (30,62). To assess recovery and
stability of RNA, we spiked each fraction with an identical
amount of SYNTH RNA (30,62) during RNA extraction.
The RNA abundance in each fraction was normalized to
SYNTH RNA recovery.
Quantitative PCR reactions were performed using
TaqMan and miRNA-speciﬁc primers (Applied Biosystems, Carlsbad, CA, USA) according to the manufacturer’s instructions. Copy DNA produced in the RT
reaction was ampliﬁed in MicroAmpTM optical 96-well
reaction plates in triplicate 20 ml reactions on an Applied
Biosystems 7900HT Thermocycler (ABI). Raw data were
analyzed with SDS Relative Quantitation Software
version 2.2.3 (ABI) using the Delta–Delta CT method.
Absolute miRNA abundance was calculated by comparing CT values of samples to dilutions of a synthetic DNA
corresponding to the complementary DNA produced by
RT for each miRNA measured (63) to make a standard
curve or by using an RNA oligo as a standard as
described (30,62).

conventional immunoﬂuorescence approaches (61). Cells
were imaged on a Nikon Eclipse 80i confocal microscope.
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measured miRNAs co-migrated with the bulk of
microvesicles, as indicated by the lack of miRNA in the
fractions most enriched in the cell-surface antigen CD81, a
marker of many microvesicles (Figure 1C). This result
supports the idea that only sub-populations of vesicles
contain miRNA (67).
In order to proﬁle the total small RNA population in
each of these fractions, RNA was isolated from the P70,
50 -end labeled with radioactive ATP and imaged by autoradiography following separation on a denaturing
polyacrylamide gel (Figure 1D). As is the case for
miRNA, different small RNA species were enriched in
different fractions; portions of the CD81-positive vesicle
population were largely devoid of small RNA species
(Figure 1C and D). Therefore, we conclude that different
miRNAs associate with different particles and that the
measured miRNAs associate with the bulk of other
small RNAs exported in vesicles and particles.
Selectively and neutrally exported miRNAs associate with
different released particles
In order to systematically deﬁne the different particles
released from breast cancer cells and their miRNA
cargo, we developed a method to purify each particle
type. This approach named ‘differential buoyant velocity
centrifugation’, fractionates released vesicles by both size
and density (Supplementary Figure S1, ‘Materials and

Methods’ section). Using this approach, we found that
each of the measured miRNAs was associated with a
distinct gradient fraction, as determined by end-point
RT–PCR (Supplementary Figure S2A) and qRT–PCR
analysis of RNA isolated from gradient fractions (Figure
2A and Supplementary Figure S2B). A similar result was
obtained with another breast cancer cell line, MCF7
(Supplementary Figure S3). These results demonstrate
that each released miRNA associates with a distinct and
speciﬁc sub-population of particles released by breast
cancer cells.
MiRNA sub-populations associate with extracellular
particles of different density
To identify and characterize the particles that are
associated with each of the miRNAs, we measured the
buoyancy mass and buoyant velocity of the different
miRNA-enriched particles. The measured density of
both neutrally released miR-16/miR-720 and selectively
exported miR-451 ranged from 1.13 to 1.18 g/ml
(Figure 2B and Supplementary Figure S1). This density
is deﬁning for exosomes (68), yet a major difference of
the s-miRNA miR-451 is that it migrated to that equilibrium density much slower than the n-miRNAs MiR-16
and miR-720 (Figure 2A and B). Furthermore, the
n-miRNAs and the s-miRNAs co-migrated with the
microvesicular surface marker CD81 (Figure 2C and D).
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Figure 1. MiRNAs exported from breast cancer cells associate with a complex population of particles. (A) Particulate complexes collected from
MDA-MB-231 cells grown in deﬁned media were cleared of debris, ﬁltered, collected by centrifugation at 70 000g (P70) and imaged by negative-stain
EM. The preparation contains cup-shaped vesicles (as indicated by arrows) and structures of different shapes (arrowheads). (B) The largest diameter
(ø) of >500 structures was measured and plotted. (C) A P70 preparation of MDA-MB-231 cells was subjected to buoyant sucrose gradient centrifugation for 18 h, and 1 ml gradient fractions (12, bottom of gradient, 1, top) were assayed for miRNA and CD81 abundance. The miRNA species of
each gradient fraction were quantiﬁed using TaqMan qRT–PCR, and each miRNA species is plotted as a proportion of the fraction with maximum
miRNA abundance, set at 1, and CD81 was measured using a dot blot probed with anti-CD81 antibody, and binding of a secondary goat-anti-mouse
IgG-Alexa 488 was measured by ﬂuorescence quantitation as described in Materials and Methods. A dot blot developed for secondary HRP antibody
binding is shown below the graph. (D) Total small RNAs were visualized after 32P end-labeling and separation by native PAGE. 19–24 ntds: RNA
species with expected size for miRNAs.
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Together, these results indicate that neutrally and selectively exported miRNAs are packaged in different
exosome-like vesicles.
MiR-1246 had an equilibrium density of 1.25 g/ml,
demonstrating that miR-1246 is not an exosomal RNA
(Figure 2A and B) because exosomes, by deﬁnition, have
a density 1.19 g/ml or less (68). The fact that miR-1246
exhibited minimal movement in the gradient raises the
possibility that it is a non-vesicular miRNA. To test
whether extracellular miR-1246 is contained within a
vesicle or not, we compared its behavior on the gradient
with that of a synthetic 22 nucleotide RNA (SYNTH)
(62), which was added to the P70 prior to gradient
centrifugation. SYNTH RNA had density equilibrium of
1.28 g/ml (Figure 2A), suggesting that the s-miRNA
miR-1246 is released from cells as a complex less dense
than naked RNA but denser than exosomes.
Taken together, these data indicate, that rather than
being randomly distributed, miRNAs whose release is
regulated by malignant transformation, associate with

particles that are different than the particles associated
with miRNAs whose release is not affected by malignant
transformation.
n-miRNAs and s-miRNAs associate with particles of
different shape and size
To distinguish physical characteristics of the particles that
are associated with each of the extracellular miRNAs, we
analyzed them by EM (Figure 3A). Both s-miRNA
miR-451 and n-miRNAs miR-16/miR-720 co-migrated
with cup-shaped vesicles, suggestive of exosomes.
However, the s-miRNA vesicles were about 86 nm in
diameter, whereas n-miRNA vesicles were twice this size
(Figure 3A and B). The s-miRNA miR-1246 peak fraction
was enriched in spheres that were smaller than the
miR-451 vesicles (Figure 3A). The association of these
miRNAs with the identiﬁed particles was conﬁrmed by
the ﬁnding that these miRNAs co-partitioned with the
visualized particles following ﬁltration (Supplementary
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Figure 2. Selectively exported MiRNAs associate with different complexes than commonly released MiRNAs. (A) P70 preparations of particles
exported by MDA-MB-231 cells were separated by buoyant speed centrifugation for the indicated number of hours, and the miRNA species were
measured using TaqMan qRT–PCR. Each miRNA species is plotted as a proportion of the fraction with maximum miRNA abundance, set at 1.
(B) Plot of peak fractions in gradients from 0 to 100 h (qexosomes indicated the gradient density expected of exosomes [1.13–1.19 g/ml,
Supplementary Figure 1]). Buoyant velocity was as follows: neutrally released MiR-16 and miR-720: 0.78 and 1.0 cm/h, respectively. Selectively
exported miRNA miR-451 and miR-1246: 0.04 and 0.2 cm/h, respectively, SYNTH RNA (0.01 cm/h). n = 4–12 for each point. Error bars: standard
deviation from the mean. The black symbol represents naked SYNTH RNA added to the gradient. (C) Gradient fractions (12, bottom of gradient, 1,
top) as in (A) were quantiﬁed for the abundance of an extracellular vesicle surface antigen, CD81 by dot blot, and the antigen abundance was
measured using ﬂuorescent quantitation. Data are plotted in (D). Colored arrows mark peak miRNA fractions as indicated in (A). CD81 is plotted
as a proportion of the fraction with maximum CD81 abundance, set at 1. Colors correspond to the same miRNA species as in (A) (miR-16 blue,
miR-451 red, miR-1246 green and miR-720 purple). The gray and the black traces are from two independent experiments.
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Figure S4A). The miRNAs were also resistant to ribonuclease treatment, suggesting that they are protected
within vesicles or by vesicle proteins (Supplementary
Figure S4B and S4C).
Overall, our data demonstrate that selectively released
miR-451 associates with vesicles that are the shape and
size of exosomes, while miR-1246 associates with unrelated spherical particles. In contrast, neutrally released
miR-16 and miR-720 of mammary epithelial cells are
released in exosome-like vesicles >100 nm.
CD44 distinguishes L-exosomes from conventional
exosomes
Vesicles >100 nm are typically not considered to be
exosomes (68) but may be referred to as exovesicles,
ectosomes or microvesicles (69). Of these, exovesicles
and ectosomes differ from exosomes in that they originate
from the plasma membrane rather than the MVB and
hence are devoid of the endosomal marker CD63 (69–
72). To help determine the origin of the large vesicles we
identiﬁed, we probed for CD63 on intact vesicles using dot
blot analyses. We detected CD63 on both the large and
small cup-shaped vesicles, suggesting an endosomal origin
for both the s-miRNA- and n-miRNA-associated vesicles

(Figure 4A–C). However, because of their distinct size, we
hypothesized that s-miRNA and n-miRNA vesicles are of
different subendosomal origin. To test this idea, we
further analyzed the vesicle surfaces by dot blot analysis,
probing for proteins preferentially transported through
different endosomal pathways (73). Most antigens tested
were in similar abundance in the two vesicles (Figure 4C).
However, enrichment of the surface antigen CD44 on the
larger exosomes distinguished them from the regular-sized
exosomes. The exclusive association of miR16/miR-720
with the CD44+ vesicles (74) suggests that n-miRNAs
are sorted through a different subendosomal compartment
than the selectively exported miRNAs. We call these
newly identiﬁed CD44-positive, large exosome-like
vesicles, L-exosomes.
MiRNA species associate with distinct exosome subpopulations
Exosome sub-populations differ in their surface proteins
(75), including CD59/PROTECTIN that restricts lysis by
complement (76). Because of this protection, the CD59positive (+) sub-population of exosomes is expected to be
particularly useful for biomarker studies. To test whether
CD59+ exosomes are enriched in a particular sub-
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Figure 3. Selectively and neutrally exported MiRNAs associate with different particles. (A) Peak miRNA fractions of a 48-h gradient were subjected
to negative EM staining. Arrows indicate the typical structures detected in these preparations, and magniﬁed in insets. (B) A plot of the largest
diameters of the structure population depicted in (A). At least 200 structures were quantiﬁed for each fraction.
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Figure 4. Large- and regular-sized exosomes; and nucleosomes have
different proteins. (A) Fractions of 6- and 90-h gradients of P70s
from MDA-MB-231 cells were probed for protein markers using quantitative dot-blot; or by western blot analysis for acetyl-H3 histone.
(B) Quantitation of data in (A). (C) Comparison of abundance of
exosome and L-exosome-associated antigens. *P < 0.05; **P < 0.01;
***P < 0.001, (n = 4). Bars represent standard deviation.

population of miRNAs, we performed immunomagnetic
separation (Figure 5A). We found that vesicles containing
CD59 had 50 times more miR-16 than the total vesicle
population, but the concentration of other analyzed
miRNAs was not enriched (Figure 5B). This observation
suggests that within the exosomal vesicle population,
sub-populations exist that bear different miRNA species.
MiR-1246 associates with nucleosomes
We found no membrane proteins associated with the
gradient fractions containing miR-1246. To deﬁne the

nature of the miR-1246 particles, we probed for a
number of nucleic acid–associated proteins and found
that these fractions contained core histones H2A and
acetylated H3 (Figure 4A and B), which are all components of nucleosomes. The size range of 30–120 nm for the
majority of complexes (Figure 3B) is consistent with the
miR-1246 structures being composed of single and
multiple nucleosomes (77,78). Such mono- and
oligonucleosomes contain RNA (79) and are released
from breast cancer cells into blood plasma, where they
might be useful for prognosis (80) and for monitoring
chemotherapeutic outcome (81).
To test whether miR-1246 is associated with nucleosomes in the cell, we performed ﬂuorescence in situ hybridization on cells using a probe to miR-1246. Consistent
with the extracellular nucleosome association, we
detected a sub-population of miR-1246 associated with
distinct 40 ,6-Diamidino-2-Phenylindole, Dihydrochloride
(DAPI)-negative nuclear bodies (nucleoli) in cells (Figure
6A and B, Supplementary Figure S5), suggesting that the
association between miR-1246 and histones is physiological. We also detected gH2Ax association (Figure 4A)
with the extracellular nucleosome-like particles, suggesting
the presence of damaged DNA. Therefore, we tested
whether DNA-damage-induced apoptosis triggers nucleosome release in the MDA-MB-231 cells. We found that
apoptosis induced by DNA damage (Figure 6C) led to an
increase in both the abundance of nucleosomes and
miR-1246 (Figure 6D and E). Alternatively, blocking the
apoptotic pathways by ectopic expression of Bcl-2 or a
dominant-negative form of caspase 9 (66) did not
change the release of exosomes or L-exosomes
(Supplementary Figure S6). This result supports the idea
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Figure 5. MiR-16 is enriched in CD59/PROTECTIN positive vesicles.
Vesicle and particle sub-populations with CD59 or g-H2Ax surface
antigen were enriched by immunomagnetic separation. (A) Bound
and remaining unbound populations of immunomagnetic beads were
probed for CD59 recovery (top panel; – indicates naked beads
incubated with P70. CD59 or g-H2Ax indicates beads bound with
these antibodies were incubated with P70). (B) MiRNA enrichment
on beads was quantiﬁed using TaqMan qRT–PCR (bottom panel).
Bars represent standard deviation (n = 4).
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that apoptosis is a source of circulating nucleosomes (80),
but not exosomes (30,82) and that miR-1246 is associated
with these nucleosomes.
Normal cells release miRNAs in a single vesicle type
The ﬁnding that n-miRNAs and s-miRNAs segregate into
different particles suggests that speciﬁc miRNA subpopulations are speciﬁcally diverted in breast cancer
cells. To test whether this property is a hallmark of
breast cancer cells, we characterized the miRNAcontaining vesicles of normal ﬁbroblast and mammary
epithelial cells. We found that in normal ﬁbroblasts, a
single vesicle type was released. These vesicles resemble
exosomes in their shape (Figure 7A), surface antigenicity
(Figure 7A and B), density, buoyancy (Figure 7B) and size
(Figure 7C), and they carry all miRNA species that we
measured (Figure 7D). No nucleosomes, which are of
similar size as exosomes but of different shape and
density (Figure 3), were found to be released from ﬁbroblasts. This observation suggests that the selective export
of miRNAs in specialized vesicles is a feature of breast
cancer cells.
To assess miRNA export in normal mammary epithelial
cells, we proﬁled miRNAs and vesicles in human milk, a
body ﬂuid produced mostly by mammary epithelial cells.
As expected, milk contained several vesicles (2,83,84),
including CD81-positive vesicles of two buoyant densities
(Figure 8A) and sizes (Figure 8B and C). However, unlike
breast cancer vesicles, both s-miRNAs miR-451 and

miR-1246 migrated in milk vesicles together, rather than
in separate vesicles as is the case during the release from
malignant cells, despite the fact that both fast- and slow
migrating vesicles are present in milk (Figure 8A).
Furthermore, the miRNAs were associated with vesicles
that barely moved in the gradient, which were enriched in
59 nm spherical particles (Figure 8D and E) and which
also contain CD81 (Figure 8A). The nature of these
vesicles is currently not clear. However, these results
indicate that miRNAs are exported differently from malignantly transformed epithelial cells than from benign
cells in the body. Overall, these data highlight the complexity of miRNA release from cells and suggest that this
process is regulated in a manner that reﬂects the origin
and transformation state of the cell.

DISCUSSION
MiRNAs are released in custom-made vesicles
This study expands the repertoire of extracellular
miRNA-associated particles to include nucleosomes and
L-exosomes. A major ﬁnding of this study is that both
n-miRNAs and s-miRNA species from malignant cells
are exported in vesicles that are not used by normal cells
(Figure 9). We discovered these miRNA-containing particles and the differential segregation of miRNA for
release into these particles by developing an approach,
differential buoyant velocity centrifugation.
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Figure 6. MiR-1246 associates with nucleosomes. (A) MCF7 cells were probed for miR-1246 using miRCURY LNA probes (top panel) and for
CD63 using antibodies (middle panel) and dyed for DNA (with DAPI, middle panel). Arrows indicate DAPI-negative regions of the nucleus
(nucleoli). (B) Overlay of the individual probes. Green arrows indicate enriched miR-1246 populations, and red arrows indicate CD63 domains.
(C) MDA-MB-231 cells were treated with etoposide, and cell death was quantiﬁed using trypan blue (n = 7). (D) Exported miR-1246 abundance was
measured by TaqMan qRT–PCR. The two-tailed P value was calculated by paired T-test (n = 4). (E) Probing of P70 gradient fractions with H2Ax
on untreated and etoposide-treated MDA-MB-231 cells. Supplementary Figure S5 shows probing of these cells with an rRNA probe for comparison
of subcellular location of these RNA species.

9134 Nucleic Acids Research, 2012, Vol. 40, No. 18

Figure 8. MiRNAs associate with different complexes in human milk. (A) P70 was prepared from fresh human milk and subjected to buoyant
velocity centrifugation for 6 or 48 h. (B) Negative stain EM of particles in major CD81 peak void of measured miRNAs. Arrows: electron-poor
globules only detectable in the peak CD81 fractions. (C) Graph of largest diameters of particles of CD81 peak fraction. (D) The abundance of
indicated miRNAs were measured in each gradient fraction after 6 h or 48 h of centrifugation by TaqMan qRT–PCR. (E) Negative stain EM of
particles in major miRNA containing fraction after 6 or 48 h of gradient centrifugation.
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Figure 7. Normal human ﬁbroblasts export MiRNAs in a single vesicle family. (A) Normal donor skin ﬁbroblasts were grown in deﬁned media, a
P70 preparation was produced and was subjected to buoyant velocity centrifugation for 6 h or (B) 92 h and probed for CD59, CD63 and HLA by dot
blot and quantiﬁed. Inset in (A): EM of peak fraction 10 of 6 h gradient. Bar = 500 nm. (C) The largest diameter of >300 vesicles was measured and
summarized. (D) Distribution of measured CD81 and miRNAs within gradient, n = 2.
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Speciﬁc miRNAs associate with some vesicles exclusively
This study demonstrates that speciﬁc miRNA species associate mutually exclusively with some vesicles. The differences in miRNA composition are more pronounced
than the quantitative differences in the surface proteins
of the vesicles that distinguish L-exosomes from conventional exosomes. Therefore, the miRNA cargo, rather
than differences in vesicle surface antigens, may be the
best markers to distinguish these vesicles. The present
studies suggest that fundamental differences in miRNA
sorting and trafﬁcking in breast cancer cells exist which
are linked to modiﬁcations of sub-endocytic pathways.
The sorting into different vesicles appears to be
sequence-speciﬁc, because s-miRNAs and n-miRNAs associate with different particles. Recently, sequence motifs
in miRNAs were suggested to provide clues regarding selective release of miRNAs (85). Thus, it is possible that
cell-type-speciﬁc release of miRNAs is regulated through
modulation of trans-acting factors that interact with
speciﬁc miRNA sequences.

that nucleosome-associated miRNAs may correlate with
breast cancer growth (81).
The vesicles subspecies contain different information
regarding the cell of origin
One practical implication of this study is that it offers
information, including speciﬁc surface proteins that are
enriched in the different vesicles that will allow for the
isolation and identiﬁcation of speciﬁc vesicle types that
could be useful for diagnostics, treatments and for understanding the role of circulating miRNAs in cell–cell
signaling. This might be important, because deﬁned
and stable products of processes such as apoptosis and
endocytosis associate with different vesicles. As all of
these processes are modiﬁed in breast cancer, the presence
of the vesicles suggests that a wealth of representative
elements of pathways deregulated in the tumor cells of
origin are present in body ﬂuids. Thus, proﬁling these particles and vesicles individually may provide accurate information regarding these different functions in the cell of
origin and reveal differences in functions these particles
and vesicles impose upon other cells after transfer.

MiRNAs released in nucleosomes
We found that miR-1246 is associated with nucleosomes.
Nucleosomes circulating in the body are likely released as
a consequence of apoptosis. The association of miR-1246
with nucleosomes ﬁts well with our ﬁnding that miR-1246
is nearly undetectable in the extracellular environment of
normal cells in culture or in mammary ﬂuids (30), because
normal cells typically undergo apoptosis at a lower frequency than cancer cells. An apoptosis-related increase
of circulating nucleosomes is known to correlate with
breast cancer progression (80), raising the possibility
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Supplementary Data are available at NAR Online: Supplementary Figures 1–6 and Supplementary References
[86–88].
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Figure 9. Characteristics of the major particles exported from breast cancer cells. Breast cancer cells export three families of particles containing
miRNAs, L-exosomes, exosomes and dense spherical particles containing histones. Exosomes and L-exosomes contain many similar surface antigens,
including CD63, an endosomal marker. However, exosomes and L-exosomes differ in the abundance of CD44, the vesicle size and the miRNA
content. Sub-populations of these vesicles contain speciﬁc miRNAs. For example, miR-16, but none of the other miRNAs associate with
CD59-positive vesicles. MiR-1246 associates with particles containing histones, which are void of vesicle surface markers. Interestingly, miRNAs
that are selectively exported from malignant mammary epithelial cells are exported in exosomes and the spherical particles, but commonly released
miRNAs miR-16 and miR-720 associate with L-exosomes. Non-canonical: miR-451 and miR-720 are processed non-canonically.
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